Publication:
[Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis].

cris.virtualsource.author-orcidb45b7422-97de-484f-9a83-b0bf5fbacd4b
datacite.rightsmetadata.only
dc.contributor.authorFunke, Manuela
dc.contributor.authorGeiser, Thomas
dc.date.accessioned2024-12-13T15:39:43Z
dc.date.available2024-12-13T15:39:43Z
dc.date.issued2016
dc.description.abstractRecent studies have shown efficacy to slow the decrease of forced vital capacity in patients with idiopathic pulmonary fibrosis. This summary refers to recent anti-fibrotic medications and describes current studies, indication for treatment and side effects, as well as discusses open questions of treatment.
dc.description.numberOfPages5
dc.description.sponsorshipUniversitätsklinik für Pneumologie
dc.identifier.pmid26884217
dc.identifier.publisherDOI10.1024/0040-5930/a000751
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/192848
dc.language.isode
dc.publisherHuber
dc.relation.ispartofTherapeutische Umschau
dc.relation.issn0040-5930
dc.relation.organizationDCD5A442BB14E17DE0405C82790C4DE2
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.title[Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis].
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage29
oaire.citation.issue1
oaire.citation.startPage25
oaire.citation.volume73
oairecerif.author.affiliationUniversitätsklinik für Pneumologie
oairecerif.author.affiliationUniversitätsklinik für Pneumologie
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.description.ispublishedpub
unibe.eprints.legacyId93081
unibe.journal.abbrevTitleTher Umsch
unibe.refereedtrue
unibe.subtype.articlecontribution

Files

Collections